Survival At One Year Among Patients With COVID-19, Acute Respiratory Failure Was More Likely If They Received Nintedanib Or Pirfenidone Antifibrotics, Study Shows

Healio (8/28, Hornick) reports, “Among patients with COVID-19 and acute respiratory failure, survival at 1 year was more likely if they received nintedanib or pirfenidone antifibrotics, according to” a study. Investigators came to this conclusion after performing “a retrospective, multi-institutional cohort study” involving “167 patients (mean age, 64.5 years; 59.3% men; 75.4% white) who received either nintedanib (Ofev, Boehringer Ingelheim; n = 127) or pirfenidone (n = 39) vs. 167 propensity score-matched control patients (mean age, 65.8 years; 59.3% men; 64.1% white).” The findings were published in BMC Pulmonary Medicine.